The Future of Lung Cancer Screening: Current Challenges and Research Priorities
Amna Burzic,Emma L O’Dowd,David R Baldwin,Emma L O'Dowd
DOI: https://doi.org/10.2147/CMAR.S293877
2022-02-16
Cancer Management and Research
Abstract:Amna Burzic, 1 Emma L O'Dowd, 1, 2 David R Baldwin 1, 2 1 Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, UK; 2 Division of Medicine, University of Nottingham, Nottingham, NG5 1PB, UK Correspondence: David R Baldwin, Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, NG5 1PB, UK, Tel +44 115 9691169, Fax +44 115 9627723, Email Lung cancer is the leading cause of cancer-related deaths worldwide, primarily because most people present when the stage is too advanced to offer any reasonable chance of cure. Over the last two decades, evidence has accumulated to show that early detection of lung cancer, using low-radiation dose computed tomography, in people at higher risk of the condition reduces their mortality. Many countries are now making progress with implementing programmes, although some have concerns about cost-effectiveness. Lung cancer screening is complex, and many factors influence clinical and cost-effectiveness. It is important to develop strategies to optimise each element of the intervention from selection and participation through optimal scanning, management of findings and treatment. The overall aim is to maximise benefits and minimise harms. Additional integrated interventions must include at least smoking cessation. In this review, we summarize the evidence that has accumulated to guide optimisation of lung cancer screening, discuss the remaining open questions about the best approach and identify potential barriers to successful implementation. Keywords: lung cancer, screening, computed tomography Lung cancer is the leading cause of cancer-related deaths worldwide because it is both common and the majority of people present clinically with late-stage disease, when even modern treatments have little impact on mortality. Early detection with low radiation dose CT (LDCT) reduces lung cancer-related mortality by detecting lung cancer at an early stage when it is amenable to potentially curative treatments. Two large randomised controlled trials, the US National Lung Screening Trial (NLST) 1 and the Dutch-Belgian NELSON Trial, 2 have shown that LDCT reduces lung cancer-specific mortality rate, and the larger of these, NLST, showed a significant all-cause mortality reduction of 6.7%. 1 Both trials provide sufficient evidence to support the implementation of screening on the basis of clinical efficacy, although there is still debate about cost-effectiveness, where the specifics of implementation are key. 3,4 Over the last ten years, since the publication of NLST, much research work has been published to inform those managing nascent screening programmes on how they should be structured. In this review, we will focus on current evidence on lung cancer screening in the UK, Europe and North America. We will describe the approach to developing a screening programme to show how each element contributes to a successful service and describe current challenges and future research priorities. To make lung cancer screening viable, it must be clinically and cost-effective. One of the essential requirements is to apply screening to a population at risk of the disease. The screening test, LDCT, is relatively expensive compared with, say, the Faecal Immunochemical Test used for colorectal screening, and so it is important to target screening in populations where the chance of finding lung cancer is sufficiently high, in other words a high-risk group. Robust selection criteria for screening will therefore reduce the number of false-positives and subsequent scanning. Although age and smoking status are known to be the greatest risk factors for developing lung cancer, several other important factors also contribute to risk. 5 The NLST and NELSON trials used age and cumulative smoking exposure in their selection criteria. The US Preventive Services Task Force (USPSTF) subsequently recommended annual lung cancer screening in 2013 for individuals aged 55–80 who had a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. 6 In July 2020, the USPSTF revised these screening recommendations to include a lower entry age of 50 years and reduced the threshold for smoking exposure to 20 pack-years. 7 However, there is concern that these criteria, although easy to apply, oversimplify lung cancer risk prediction by ignoring important risk factors, such as family history of lung cancer, smoking intensity, personal history of other respiratory diseases and asbestos exposure. Several multi-variable risk-prediction models to assess the risk of developing lung cancer have been developed with the aim to increase pre-test p -Abstract Truncated-
oncology